Introduction
A tight balance between cellular survival, proliferation and apoptosis exists to maintain appropriate cell numbers and homeostasis in the hematopoietic compartment. Aberrations in the complex cytokine and transcription factor network that regulate hematopoiesis lead to hematological disorders (Liebermann et al., 1995; Moqattash et al., 1998; Zhu et al., 2002; Tenen, 2003; Rosmarin et al., 2005) . The myeloid cell compartment provides an excellent model to study molecular processes associated with homeostasis of blood cells, including cellular proliferation, survival and programmed cell death (i.e., apoptosis) and how aberrations in these processes result in oncogenesis .
The p53 tumor suppressor gene encodes for a transcription factor that plays a seminal role in the response of mammalian cells to physiological and environmental stress (May et al., 1999) . p53 was implicated as a major mediator of cell cycle arrest and/or apoptosis in the response of mammalian cells to stress May et al., 1999; Oren, 2003) . It is not surprising, therefore, that p53 mutations and functional inactivation was linked to the pathology of more than half of all cancers (Levine, 1997) .
Salient features of M1 myeloid leukemic cells are that they lack p53, and respond to the physiological survival factor IL-6. The ability of wild-type p53 to induce apoptosis was first demonstrated using M1 cells that had been genetically engineered to express a temperaturesensitive (ts) p53 transgene (Yonish-Rouach et al., 1991; Selvakumaran et al., 1994) . Using these cells, it was also shown that the survival factor IL-6 protects the cells from p53-mediated apoptosis. This seminal observation led to research showing that p53 is involved in the maintenance of normal myeloid cell homeostasis in response to low concentration of viability factors, or following exposure to DNA-damaging agents (Lotem et al., 1993) . Evidence was obtained that elevated levels of IL-6 are associated with leukemogenesis (Hawley et al., 1992; Manakova et al., 2001; Trikha et al., 2003) .
Using M1 cells that express ts p53, we, in collaboration with Dr John Reed's group, were the first to link induction of the proapoptotic Bax protein and suppression of prosurvival Bcl-2 protein to p53-mediated apoptosis Selvakumaran et al., 1994) . However, clear mechanistic insight as to exactly how p53 induces apoptosis of M1 myeloid leukemia cells and how the survival factor IL-6 protects the cells from this apoptosis is still lacking (Lotem et al., 2003 (Lotem et al., , 2004 . Thus, the objective of the present work was to determine the molecular pathways by which p53 mediates apoptosis of myeloid leukemic cells, and to delineate the mechanism by which IL-6 functions as a survival factor against p53-induced apoptosis.
Results
p53 induces apoptosis of M1 myeloid leukemia cells via the Fas/Fas ligand death receptor pathway, with the intrinsic mitochondrial pathway playing an ancillary role M1-t-p53 cells containing a tsp53 (Val-135-Ala) transgene (Selvakumaran et al., 1994) were used to investigate the effects of p53 activation in the presence and absence of the survival factor IL-6. Activation of wildtype p53 function by transferring M1-t-p53 cells from 371C to permissive temperature of 321C resulted in rapid apoptosis (Figure 1a ). IL-6 (50 ng/ml) effectively inhibited this p53-induced apoptosis, with 80% of M1-tp53 cells viable at 18 h.
As the Fas/CD95 death receptor pathway is an archetypal apoptotic pathway in hematopoietic cells (Niho et al., 1998; Amanullah et al., 2002) , we asked whether this pathway is involved in mediating p53-induced apoptosis in M1 cells. Using fluorescein isothiocyanate (FITC)-conjugated Fas receptor antibody and fluorescence-activated cell sorter (FACS) analysis, only 9% of M1 and M1-t-p53 cells incubated at 371C expressed Fas receptor (Figure 1b) . Following incubation at 321C, M1 cells remained viable and Fas receptor was not upregulated (data not shown). However, activation of p53 at 321C in M1-t-p53 cells resulted in a rapid increase in cell surface Fas receptor expression, preceding the kinetics of apoptosis (Figure 1c) .
To assess the role of the Fas/CD95 pathway in the execution of p53-mediated apoptosis in M1-t-p53 myeloid leukemia cells, we asked if blocking the Fas/ CD95 death receptor pathway, via antagonistic Fas/ CD95 antibody, would abrogate the apoptotic response. The Fas/CD95 blocking antibody significantly abrogated p53-mediated apoptosis at 321C (Figure 1d) , with 1.5 mg/ml blocking antibody conferring maximum protection (data not shown).
Next, we asked whether activation of p53 results in activation of caspases 8 and 10, apical initiator caspases of the Fas/CD95 pathway, and if so, whether treatment of the cells with antagonistic Fas antibody would prevent activation of these caspases. p53 induced both caspase 8 and caspase 10 activity, and Fas blocking antibody reduced caspase activation (Figure 1e and f) .
As Fas blocking antibody reduced activation of caspases 8 and 10, we asked whether inhibition of these caspases would abrogate p53-induced apoptosis, and if so, how it would compare the ability of IL-6 to protect against p53-mediated apoptosis (Figure 1g ). Inhibition of both caspases 8 and 10 afforded higher protection against p53-mediated apoptosis, compared to inhibition of each one separately, similar to protection afforded by Fas blocking antibody, and almost as effective as IL-6. This implies that the previously reported p53-mediated upregulation of proapoptotic Bax and downregulation of antiapoptotic Bcl2 in M1-t-p53 cells, associated with the intrinsic mitochondrial apoptotic pathway, is ancillary to the extrinsic Fas/CD95 apoptotic pathway in mediating p53-induced apoptosis of MI cells.
IL-6 prevents apoptosis via the Fas/CD95 pathway downstream of the Fas receptor IL-6 protection against p53-mediated apoptosis does not result in the degradation of p53 protein or alter its function (data not shown; Selvakumaran et al., 1994) . Therefore, we investigated how IL-6 affects the Fas/ CD95 death receptor pathway, the major effector of p53-induced apoptosis in M1 cells. We first asked whether IL-6 protects by preventing upregulation of Fas receptor. IL-6 treatment did not decrease Fas/CD95 receptor expression (Figure 2a) . Rather, IL-6 treatment increased Fas/CD95 receptor expression, consistent with our previous data (Amanullah et al., 2000) . Furthermore, Western blot analysis indicated that IL-6 did not regulate Fas ligand protein, which was constitutively expressed (Figure 2b ). These data indicate that IL-6 does not exert its survival role at the Fas/CD95 ligand or receptor levels.
In an active Fas/CD95 death-inducing signaling complex (DISC), caspase 8 undergoes autocatalysis and activation, cleaving the 55 kDa c-Flip protein to the 43 kDa form (see Figure 8 ; Krueger et al., 2001 ). Therefore we investigated whether IL-6 prevented p53-induced activation of caspase 8 and cleavage of c-Flip. The 55 kDa c-Flip protein was abundant in both untreated M1 and M1-t-p53 cells (Figure 3a) . Functional activation of p53 resulted in cleavage of c-Flip protein and the appearance of a 43-kDa band, concomitant with caspase 8 activation. IL-6 treatment prevented p53-induced c-Flip cleavage and reduced activation of caspase 8 (Figure 3b ). Thus, these data indicate that IL-6 prevents activation of the Fas/CD95 DISC. PI3K/Akt is essential for IL-6 protection against p53-induced apoptosis in myeloid leukemic cells To determine the mechanism by which IL-6 prevents Fas/CD95 DISC activity, we assessed contributions of signaling pathways emanating from the IL-6 receptor, including the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK), Jak/Stat and PI3K/Akt pathways (Hirano et al., 2000; Heinrich et al., 2003) . First we ruled out the MAPK/ ERK and Jak/Stat pathways. (data not shown). Next we asked whether IL-6 treatment of M1-t-p53 results in phosphorylation-dependent activation of Akt, and if so, whether inhibition of the PI3K/Akt pathway with its specific inhibitor LY294002, (Vlahos et al., 1994; Yano et al., 1995; Hu et al., 2000; Heinrich et al., 2003) , would abrogate IL-6 protection. Ly294002 (100 mm) was used in the presence and absence of IL-6 treatment and p53 activation (Figure 4 ). IL-6 treatment of M1-t-p53 cells resulted in Akt phosphorylation at both 37 and 321C (Figure 4a ), as early as 1 h following IL-6 treatment (data not shown). Inhibition of Akt phosphorylation with Ly294002, having no effect on IL-6-treated cells at 371C, abrogated IL-6 protection against p53-induced pathway blocking antibody abrogates p53-mediated apoptosis. M1-t-p53 cells were either untreated or treated with either Fas/CD95 blocking antibody (1.5 mg/ml) or isotype control antibody (1.5 mg/ml) for 2 h before shifting cells to 321C for 14 h, and apoptosis/survival was quantified as previously described. p53 induces activation of caspase 8 (e) and caspase 10 (f) and Fas/CD95 pathway blocking antibody abrogates this p53-induced caspase activation. Spectrophotometric detection of cleaved substrates specific for caspase 8 or caspase 10 was performed at 14 h following shift to 321C. Treatment with blocking antibody was as described in (d) above. Fold increase in caspases 8 and 10 activity was calculated by comparison of treated samples to an uninduced control. (g) Inhibition of caspases 8 and 10 reduces p53-induced apoptosis. Percent survival of M1-t-p53 cells, either untreated or treated with IL-6, Fas/CD95 blocking antibody (1.5 mg/ml), inhibitors of caspases 8 and 10 (75 mM each/150 mm total), caspase 8 inhibitor alone (150 mM), or caspase 10 alone (150 mM) for 2 h before shifting to 321C for 14 h. Apoptosis/survival was quantified as previously described. For all experiments described, results are average of three independent experiments 7s.d.
apoptosis. This demonstrates that the PI3K/Akt prosurvival pathway is activated upon IL-6 treatment and is essential for IL-6 protection against p53-induced apoptosis ( Figure 4 ).
IL-6-mediated PI3K/Akt activation counters Fas/CD95 DISC activation in p53-mediated apoptosis As IL-6 treatment resulted in activation of the PI3K/ Akt pathway, essential for IL-6-mediated abrogation of p53-induced apoptosis, and IL-6 also prevented Fas/ CD95 DISC activity, we hypothesized that activation of PI3K/Akt would prevent Fas/CD95 DISC activity induced by p53. To test this conjecture, we assessed if Akt inhibition and abrogation of IL-6 protection from p53-mediated apoptosis resulted in activation of caspase 8 and cleavage of c-Flip protein. As shown in Figure 5 , inhibition of PI3K/Akt resulted in c-Flip protein cleavage and caspase 8 activation, indicative of DISC activity, demonstrating that IL-6-mediated activation of PI3K/Akt is necessary to prevent Fas/CD95 DISC activity.
IL-6-mediated PI3K/Akt activation also counters p53-induced apoptosis via the intrinsic mitochondrial pathway As Bax and Bcl-2 are p53 targets, and IL-6 protection is more effective than either Fas blocking antibody or caspases 8 and 10 inhibitors (Figure 1g ), we investigated whether IL-6-mediated Akt signaling also targets the mitochondria, an 'intrinsic' regulator of apoptosis (Gottlieb et al., 2000) . First, we asked whether the Bcl-2 proteins Mcl-1, Bcl-2, Bcl-x1 and Bax are regulated by IL-6, and if so, whether inhibition of Akt affects their expression. Western blot analysis (Figure 6a) shows that low basal Mcl-1 protein expression in MI-t-p53 cells is significantly increased after IL-6 treatment at both temperatures, and inhibition of PI3K/Akt kinase suppressed this Mcl-1 induction.
Bax protein expression increased following activation of p53, and remained elevated following IL-6 treatment. Both IL-6 treatment and activation of p53 at 321C, resulted in decreased Bcl-2 protein levels. In contrast, Bcl-xl protein expression was robust overall, under any of the treatment conditions. These observations indicate that IL-6-mediated Akt phosphorylation, necessary for survival and blocking DISC activation, is also required for elevated expression of the antiapoptotic Mcl-1, which likely contributes to overcoming elevated Bax induced by p53.
In apoptotic cells, as a consequence of the function of proapoptotic Bcl-2 family members, voltage potential across the mitochondrial membrane drops as mitochondria rupture. Changes in voltage potential were measured using tetramethyl rhodamine ethyl ester (TMRE), a fluorescent voltage-sensitive dye that binds specifically to intact mitochondria. A drop in the mitochondrial PI3K/Akt signaling mediates IL-6 protection against p53-induced apoptosis DL Vesely et al membrane potential during membrane rupture in early apoptosis causes decreased TMRE binding, which is measured by FACS analysis. As shown in Figure 6b , 14 h after shift from 37 to 321C, 32% of M1-t-p53 cells exhibited disrupted voltage potential. IL-6 protection prevented this drop in membrane potential; only 3% of cells exhibited a drop, whereas inhibiting Akt phosphorylation in IL-6-treated cells resulted in disrupted mitochondrial membrane potential in 41% of cells. These results indicate that the IL-6-mediated PI3K/Akt pathway alters the ratio and function of pro-and antiBcl-2 proteins, to maintain mitochondrial membrane voltage potential. When mitochondria rupture, cytochrome c is released, activating capase 9 which in turn processes the downstream effector caspases 3 and 7, leading to apoptosis (Figure 8 ). We asked if caspase 9 correlates with the apoptotic response. Caspase 9 was uncleaved and inactive in M1-t-p53 cells at 371C with all treatments (Figure 6c ). Activation of p53 at 321C resulted in pro-caspase 9 cleavage into 39 and 37 kDa subunits; IL-6 prevented this cleavage, whereas inhibition of PI3K/Akt phosphorylation resulted in caspase 9 cleavage. Thus, caspase 9 activity is detected whenever the cells undergo apoptosis. To determine whether caspase 9 activation contributed to p53-mediated apoptosis, the effect of caspase 9 inhibition on apoptosis was assessed (Figure 6d ). Inhibition of caspase 9 together with 8 and 10 increased cell viability, provided by inhibiting caspases 8 and 10, from 60 to 70%.
These data demonstrate that IL-6-mediated Akt phosphorylation provides additional protection against p53-mediated apoptosis at the mitochondrial level by the induction of Mcl-1, which promotes mitochondrial membrane integrity and prevents caspase 9 activation.
IL-6-mediated PI3K/Akt prosurvival signaling facilitates nuclear factor-kappaB (NF-kB) activation As NF-kB is a major prosurvival pathway , it was of interest to determine whether IL-6 and PI3K/Akt prosurvival signaling activates this pathway. IKBa is an inhibitory protein that maintains NF-kB in the cytoplasm. Upon cytokine signaling, IKBa is phosphorylated and inactivated, allowing the p65(RelA)-NF-kB complex to translocate into the nucleus to transcribe genes involved in cell viability (Ghosh and Karin, 2002; Hayden and Ghosh, 2004) . Hence, phosphorylation of IKBa and nuclear localization of the NF-kB subunit is indicative of NF-kB activation. Figure 7a shows that IL-6 treatment resulted in phosphorylation of IKBa in the presence and absence of functional p53 activation. Inhibition of PI3K/Akt with Ly294002 abrogated IL-6-induced IKBa phosphorylation. Concomitant with phosphorylation of IKBa, there was nuclear localization of p65 NF-kB (Figure 7b ). When PI3K/Akt was inhibited, IKBa was not phosphorylated, p65 NF-kB did not localize to the Figure 4 The PI3K/Akt pathway is essential for IL-6 protection against p53-mediated apoptosis in M1t-p53 cells. M1-t-p53 cells were subjected to IL-6 treatment and/or functional activation of p53 for 14 h. Ly294002 (100 mM) was used to inhibit Akt activation, when indicated. (a) Western blots were used to assess total and phosphorylated Akt. (b) Cell viability was determined by staining cells with Annexin/PI, followed by FACS analysis. nucleus and the cells underwent apoptosis. These data demonstrate that NF-kB is a target of IL-6-mediated PI3K/Akt pathway activation, and is likely to contribute to IL-6 protection against p53-induced apoptosis.
Discussion
This work provides novel insights into mechanisms via which p53 induces apoptosis of myeloid cells and how the survival factor IL-6 protects from this apoptosis (Figure 8) . The knowledge gained, increases the understanding of how the functions of the p53 tumor suppressor and the IL-6 survival factor impact on each other to regulate normal hematopoiesis, and what types of lesions may perturb this process.
Using M1-t-p53, we have previously linked p53 activation to upregulation of proapoptotic Bax and downregulation of prosurvival Bcl-2 Selvakumaran et al., 1994) . Here, we determined that p53-induced apoptosis in myeloid leukemic cells is effected via the Fas/CD95 death receptor pathway. We have shown that p53-mediated apoptosis of M1 cells involves rapid activation of the proapoptotic Fas/CD95 death pathway and the intrinsic mitochondrial pathway, resulting in activation of caspases 8, 9 and 10 (Figure 8 ). Either Fas blocking antibody or inhibition of the apical caspases 8 and 10 were each almost as effective as IL-6 in abrogating p53-mediated apoptosis. Recently, it was pointed out that it is controversial whether caspase 10 is in the mouse genome. In this light, it is possible that instead of blocking the activity of caspase 10, we blocked the activity of caspase 3, a more downstream effector of caspase 8, which is also a component of the extrinsic Fas/CD95 pathway, and allegedly has high affinity for the caspase 10-specific AEVD peptide (Garcia-Calvo et al., 1998) . Whatever may be the case, these observations argue that p53 regulation of the Bcl-2 members Bax and Bcl-2, associated with the intrinsic mitochondrial apoptotic pathway, is ancillary to the extrinsic Fas/CD95 apoptotic pathway in mediating p53-induced apoptosis of M1 cells. There is still much debate regarding the importance of Fas in p53-mediated PI3K/Akt signaling mediates IL-6 protection against p53-induced apoptosis DL Vesely et al apoptosis (Owen-Schaub et al., 1995; Strasser et al., 1995; Bennett et al., 1998; O'Connor et al., 2000; Michalak et al., 2005) . Thus, our data add credence to the importance of the Fas/CD95 pathway in p53-mediated apoptosis.
Our study provides novel insights into how the survival factor IL-6 protects against p53-induced apoptosis. We show that IL-6 protects against p53-induced apoptosis via activation of the PI3K/Akt survival pathway (Figure 8 ). IL-6-induced PI3K/Akt phosphorylation by 1 h, before DISC activation, which is not detected until 6 h following p53 activation in the absence of IL-6 (data not shown). Inhibition of the PI3K/Akt pathway abrogated IL-6 protection from p53-mediated apoptosis, demonstrating that PI3K/Akt is essential for IL-6 prosurvival signaling.
The Fas DISC-associated caspase 8 activation and c-Flip cleavage that occurred owing to PI3K/Akt inhibition, indicates that IL-6-mediated Akt phosphorylation protects against p53-mediated apoptosis by modulation of the DISC within the Fas/CD95 death receptor pathway. These data are the first to demonstrate that IL-6 prosurvival signaling invokes PI3K/Akt to counter the Fas/CD95 pathway and facilitate escape from p53-mediated apoptosis. While this work was in progress, Uriarte et al. (2005) has shown that inhibition of PI3K/ Akt in T lymphocytes resulted in increased Fas/CD95 DISC formation, caspase 8 activation and apoptosis.
DISC formation is the process of Fas/CD95 receptor interaction with Fas-associated death domain (FADD) and pro-caspase 8 (Kischkel et al. 1995) . Therefore, several possibilities exist for how IL-6-mediated PI3K/ Akt activation precisely impacts the Fas/CD95 DISC. Akt may alter the efficiency of DISC formation by affecting the intracellular levels of FADD. It is possible that Akt may phosphorylate one or more of the seven serine residues in FADD to hinder its recruitment to the FAS receptor. Alternatively, Akt may phosphorylate FADD after it has bound to FAS receptor, to hinder recruitment of pro-caspase 8 and c-Flip. While the kinase modifying FADD phosphorylation is yet to be determined, these possibilities are consistent with accumulating evidence suggesting that phosphorylation of FADD functions in controlling pathways of cellular activation and proliferation (Zhang et al., 2004; Chen et al., 2005) . These possibilities are subjects of future investigations.
We also show for the first time that IL-6-induced PI3K/Akt prosurvival signaling against p53-induced apoptosis targets the intrinsic mitochondrial apoptotic pathway. Mcl-1 expression in MI-t-p53 cells was significantly increased after IL-6 treatment. Inhibition of PI3K/Akt resulted in dampened Mcl-1 expression, perturbations in mitochondrial membrane voltage potential and caspase 9 activation (Figure 8 ). Inhibition of caspase 9 enhanced the protection of caspases 8 and 10 inhbition against p53-induced apoptosis. This highlights the role of mitochondria as an additional facilitator of p53-mediated apoptosis. However, that either Fas blocking antibody or inhibitors of caspases 8 and 10 reduced p53-induced apoptosis almost as effectively as IL-6 treatment, argues that the intrinsic mitochondrial pathway is ancillary to the extrinsic Fas pathway.
While this work was in progress Birkenkeamp et al. (2004) reported that NF-kB is a target of PI3K/Akt. Consistent with this report, we found that NF-kB is a target of the PI3K/Akt pathway, activated by IL-6. This suggests that IL-6-mediated PI3K/Akt activity, in addition to its antagonistic roles on Fas/CD95 and mitochondrial apoptotic pathways, promotes NF-kB prosurvival activity. As Takahashi et al. (2005) reported that NF-kB increases IL-6 expression in acute myeloid leukemic cells, it is possible that IL-6-induced NF-kB activation acts in a positive feedback loop to drive the expression of more IL-6, thereby enhancing survival and leukemogenicity.
In conclusion, this work illuminates a model, whereby IL-6 protection from p53-mediated apoptosis in myeloid cells is mediated by the PI3K/Akt pathway, which on the one hand, counteracts the extrinsic Fas/CD95 and intrinsic mitochondrial apoptotic pathways, and on the other, promotes activation of NF-kB (Figure 8) . Although the precise mechanism remains unknown, IL-6-induced PI3K/Akt activity appears to target the extrinsic Fas/CD95 pathway at the DISC, and targets the mitochondria by upregulating the expression of Mcl-1. Finally IL-6-induced PI3K/Akt activity promotes activation of NF-kB. These observations have broad implications in understanding how cells that develop the ability to produce an autocrine survival factor can activate a major prosurvival pathway to thwart tumor suppressor surveillance function by the tumor suppressor protein p53, to contribute to leukemogenesis.
Materials and methods
Cells and cell culture M1 myeloblastic leukemia cells are devoid of p53. The M1-tp53 cell line (Selvakumaran et al., 1994) , contains a p53 transgene coding for a ts p53 protein (Ala to Val at aa 135), which is wild type at 321C and non-functional at 371C. Cells were cultured in Dulbecco's modified Eagle's medium (DMEM; GibcoBRL, Gaithersburg, MD, USA) supplemented with 1% penicillin (GibcoBRL) and 10% heat-inactivated horse serum (GibcoBRL), in a humidified atmosphere containing 10% CO 2 at 371C. For functional activation of p53, M1-t-p53, cells were shifted to permissive temperature (321C). IL-6 (Amgen Inc., Thousand Oaks, CA, USA) was used at 50 ng/ml. Annexin/propidium iodide staining for apoptosis Apoptosis was measured using Annexin V-FITC Apoptosis Detection KitII (BD PharMingen, San Diego, CA, USA). FACS analysis was performed with a FACS calibur cytometer (Becton Dickinson, San Jose, CA, USA). The CellQuest software (Becton Dickinson) was used to analyze data.
Assays for caspases 8 and 10 activity Caspase 8 activation was measured using the ApoAlert Caspase Colorimetric Assay Kit (BD Bioscience, San Diego, CA, USA, cat. no. K2027-2). To confirm specificity of the protease reaction, control apoptotic samples were treated with caspase 8 irreversible inhibitor IETD-fmk before addition of IETD-pNA substrate. Caspase 10 activation was measured using the caspase 10 Colorimetric Protease Assay Kit (BioVision Inc., Mountain View, CA, USA; cat. no. K125-100). Samples treated with caspase 10 inhibitor AEVD-fmk were used as a negative controls. Flow cytometric analysis of CD95 receptor cell surface expression 2 Â 10 7 cells per sample were harvested by centrifugation (4 000 r.p.m., 5 min), washed twice in phosphate-buffered saline (PBS), resuspended in 100 ml of PBS and stained with 0.24 mg FITC-conjugated anti-CD95 antibody (cat. no. 554257, BD Pharmingen) on ice for 30 min. After washing twice with PBS, cells were subjected to flow cytometric analysis.
Inhibitors of Fas
Protein extraction and immunoblotting 7.5-10 Â 10 6 cells were harvested and protein extracted using RIPA lysis buffer (150 mM NaCl, 50 mM Tris-HCl pH 8.0, 15% NP-40, 0.5% sodium deoxycolate and 0.1% SDS) supplemented with protease inhibitors (Sigma: 2 mg/ml leupeptin, 2 mg/ml aprotinin, 1 mM phenymethylsulfonyl fluoride (PMSF) 1 mM pepstatin-A and 1 mM dithiothreitol (DTT)). For analysis of nuclear and cytoplasmic localization of p65 NF-kB subunit, NE-PER Nuclear and Cytoplasmic Extraction Kit (Pierce, Rockford, IL, USA, cat. no. 78833) was used.
Protein concentrations were determined by BCA method (BioRad Laboratories). 60 mg of each lysate was resolved on 10 or 12% sodium dodecyl sulfate (SDS)-polyacrylamide gels; proteins were transferred to Immobilon-P transfer membrane (Millipore, Bedford, MA, USA) in 3-[cyclohexylamino]-1-propanesulfonic acid buffer (CAPS) buffer, 10% methanol at 65 V for 1 h. The membrane was blocked with 5% non-fat milk in 1 Â PBS/0.05% Tween 20 for 1 h at room temperature, and was probed with primary antibodies 16-20 h at 401C, followed by incubation with horse radish peroxidase (HRP)-labeled anti-rabbit or anti-mouse IgG (Amersham Life Sciences, Buckinghamshire, UK) at dilution of 1:5000 for 1 h at room temperature. The blot was developed using enhanced chemiluminescence kit (Cell Signaling Technologies, Beverly, MA, USA). Western blots were stripped using Restore stripping buffer (Pierce) for 15 min and reprobed with fresh antibody. Equal loading was confirmed by Ponceau S stain and actin probing. Assay for mitochondrial membrane potential MitoTracker Red CMXRos (cat. no. M7512, Molecular Probes, Eugene, OR, USA) monitored mitochondria function. CMXRos is an electrophilic dye that accumulates in active mitochondria. The spectral characteristics of CMXRos (Ex 579 nM and Em 599 nM) were detected by flow cytometry on the FL2h channel. 1 Â 10 6 cells were centrifuged (4000 r.p.m., 5 min), washed in PBS and resuspended in DMEM with 25 nM CMXROS dye prewarmed to 371C, and incubated at 371C for 30 min. Following centrifugation, cells were washed in PBS twice, resuspended in 0.5 ml PBS and analyzed by flow cytometry.
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